Ensitrelvir

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Ensitrelvir, sold under the brand name Xocova, is an antiviral medication used as a treatment for COVID-19 and as post-exposure prophylaxis (PEP) to prevent COVID-19 infections following exposure. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth. The most common adverse events include transient decreases in high-density lipoprotein and increased blood triglycerides.

Ensitrelvir, sold under the brand name Xocova, is an antiviral medication used as a treatment for COVID-19 and as post-exposure prophylaxis (PEP) to prevent COVID-19 infections following exposure. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth. The most common adverse events include transient decreases in high-density lipoprotein and increased blood triglycerides.

History

, ensitrelvir had reached Phase III clinical trials. The Japanese government is reportedly considering allowing Shionogi permission to apply for approval for medical use before the final steps of trials are completed, potentially speeding up the release for sale. This conditional early approval system has previously been used in Japan to accelerate the progression to market of other antiviral drugs targeting COVID-19, including remdesivir and molnupiravir. In a study of 428 patients, viral load was reduced, but symptoms were not significantly reduced. In February 2022, the company sought emergency approval from regulators in Japan. Shionogi announced they had reached a preliminary agreement to supply 1 million doses to the Japanese government once the drug is approved. The CEO said they could have capacity to make 10 million doses a year.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370836531 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

28 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.